The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
Today, July 23, 2026, macro headwinds, including rising oil prices and Treasury yields, weighed on crypto sentiment as key legislation appears less likely to pass.
This company providing satellite-based global geospatial data reported a notable insider sale after a massive increase in share price over the past 12 months.
SpaceX has multiple powerful growth engines, but its three-year stock return will depend on whether execution can keep pace with its premium valuation.
Principal Executive Officer Ricardo Dutra Da Silva liquidated his entire indirect position, reducing total equity holdings by 13% while maintaining 347,830 directly held shares.
With trade tensions making headlines once again, this TSX stock could deliver the great stability that many investors look for when markets become unpredictable.
A $30,000 TFSA invested in these two monthly dividend stocks could generate about $140 in monthly tax-free cash flow while offering room for long-term growth.
Both funds own long-term bonds, but the risks they carry are completely different. Here is how to choose between corporate credit and government safety.
Earning $100 a month from your TFSA is more achievable than many investors think. Here are two monthly dividend stocks that deserve a closer look today.
TELUS (TSX:T) stock looks like a compelling TSX dividend stock to buy, with an 11.7% yield, fresh leadership, and AI investments that could deliver lasting income.
Two profitable Canadian royalty stocks have slipped into “oversold” territory (RSI below 30), potentially creating a rare clearance moment near market highs.
VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.
Supported by healthy occupancy rates, robust expansion pipelines, and favourable industry fundamentals, these two REITs are excellent choices for income-focused investors.
Meta's next quarterly report will be about far more than ad revenue -- it could reveal whether Zuckerberg is building the world's next AI cloud giant or simply spending at an unprecedented pace.
Palantir may deliver the biggest gains if its AI momentum continues, but Lockheed Martin's lower valuation and government-backed demand make it the more attractive five-year investment for most investors.
The Nasdaq dropped 2.6% as mega-cap tech earnings arrived with a reality check. Rising oil prices and ballooning AI capex are weighing on market sentiment.
